- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01114217
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
Visão geral do estudo
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
British Columbia
-
Vancouver, British Columbia, Canadá
- Clinical Trial Site
-
-
New Brunswick
-
Saint John, New Brunswick, Canadá
- Clinical Trial Site
-
-
Ontario
-
London, Ontario, Canadá
- Clinical Trial Site
-
Thornhill, Ontario, Canadá
- Clinical Trial Site
-
Vaughan, Ontario, Canadá
- Clinical Trial Site
-
-
Quebec
-
Pointe-Claire, Quebec, Canadá
- Clinical Trial Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos
- Clinical Trial Site
-
Mobile, Alabama, Estados Unidos
- Clinical Trial Site
-
Montgomery, Alabama, Estados Unidos, 36106
- Clinical Trial Site
-
Montgomery, Alabama, Estados Unidos, 36116
- Clinical Trial Site
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85032
- Clinical Trial Site
-
Phoenix, Arizona, Estados Unidos, 85015
- Clinical Trial Site
-
Tucson, Arizona, Estados Unidos, 85710
- Clinical Trial Site
-
Tucson, Arizona, Estados Unidos, 85712
- Clinical Trial Site
-
-
California
-
Anaheim, California, Estados Unidos
- Clinical Trial Site
-
Bakersfield, California, Estados Unidos
- Clinical Trial Site
-
Buena Park, California, Estados Unidos
- Clinical Trial Site
-
Colton, California, Estados Unidos
- Clinical Trial Site
-
Los Angeles, California, Estados Unidos, 90036
- Clinical Trial Site
-
Los Angeles, California, Estados Unidos, 90057
- Clinical Trial Site
-
Los Angeles, California, Estados Unidos
- Clinical Trial Site
-
Mission Hills, California, Estados Unidos
- Clinical Trial Site
-
Orange, California, Estados Unidos
- Clinical Trial Site
-
San Diego, California, Estados Unidos, 92103
- Clinical Trial Site
-
San Diego, California, Estados Unidos, 92123
- Clinical Trial Site
-
San Diego, California, Estados Unidos, 92121
- Clinical Trial Site
-
-
Colorado
-
Pueblo, Colorado, Estados Unidos
- Clinical Trial Site
-
-
Connecticut
-
Bristol, Connecticut, Estados Unidos
- Clinical Trial Site
-
Groton, Connecticut, Estados Unidos
- Clinical Trial Site
-
-
Florida
-
Boynton Beach, Florida, Estados Unidos, 33426
- Clinical Trial Site
-
Boynton Beach, Florida, Estados Unidos, 33472
- Clinical Trial Site
-
Clearwater, Florida, Estados Unidos, 33759
- Clinical Trial Site
-
Clearwater, Florida, Estados Unidos, 33756
- Clinical Trial Site
-
Hialeah, Florida, Estados Unidos
- Clinical Trial Site
-
Holiday, Florida, Estados Unidos
- Clinical Trial Site
-
Inverness, Florida, Estados Unidos
- Clinical Trial Site
-
Margate, Florida, Estados Unidos
- Clinical Trial Site
-
Miami, Florida, Estados Unidos, 33126
- Clinical Trial Site
-
Miami, Florida, Estados Unidos, 33143
- Clinical Trial Site
-
Miami, Florida, Estados Unidos, 33144
- Clinical Trial Site
-
Miami, Florida, Estados Unidos, 33175
- Clinical Trial Site
-
Miami, Florida, Estados Unidos, 33135
- Clinical Trial Site
-
Miami Lakes, Florida, Estados Unidos
- Clinical Trial Site
-
Naples, Florida, Estados Unidos
- Clinical Trial Site
-
Vero Beach, Florida, Estados Unidos
- Clinical Trial Site
-
West Palm Beach, Florida, Estados Unidos
- Clinical Trial Site
-
Zephyrhills, Florida, Estados Unidos
- Clinical Trial Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Clinical Trial Site
-
Atlanta, Georgia, Estados Unidos, 30342
- Clinical Trial Site
-
Atlanta, Georgia, Estados Unidos, 30312
- Clinical Trial Site
-
Decatur, Georgia, Estados Unidos
- Clinical Trial Site
-
Dublin, Georgia, Estados Unidos
- Clinical Trial Site
-
Sandy Springs, Georgia, Estados Unidos
- Clinical Trial Site
-
Stockbridge, Georgia, Estados Unidos
- Clinical Trial Site
-
-
Illinois
-
Aurora, Illinois, Estados Unidos
- Clinical Trial Site
-
Chicago, Illinois, Estados Unidos, 60616
- Clinical Trial Site
-
Skokie, Illinois, Estados Unidos, 60076
- Clinical Trial Site
-
Skokie, Illinois, Estados Unidos
- Clinical Trial Site
-
Springfield, Illinois, Estados Unidos
- Clinical Trial Site
-
-
Kansas
-
Wichita, Kansas, Estados Unidos
- Clinical Trial Site
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos
- Clinical Trial Site
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos
- Clinical Trial Site
-
Hollywood, Maryland, Estados Unidos
- Clinical Trial Site
-
-
Michigan
-
Bay City, Michigan, Estados Unidos, 48706
- Clinical Trial Site
-
Bay City, Michigan, Estados Unidos
- Clinical Trial Site
-
Wyoming, Michigan, Estados Unidos
- Clinical Trial Site
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos
- Clinical Trial Site
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos
- Clinical Trial Site
-
-
New Jersey
-
Lawrenceville, New Jersey, Estados Unidos
- Clinical Trial Site
-
Neptune, New Jersey, Estados Unidos
- Clinical Trial Site
-
Plainsboro, New Jersey, Estados Unidos
- Clinical Trial Site
-
Voorhees, New Jersey, Estados Unidos
- Clinical Trial Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos
- Clinical Trial Site
-
-
New York
-
Brooklyn, New York, Estados Unidos
- Clinical Trial Site
-
New York, New York, Estados Unidos, 10038
- Clinical Trial Site
-
-
North Carolina
-
Raleigh, North Carolina, Estados Unidos
- Clinical Trial Site
-
Winston-Salem, North Carolina, Estados Unidos
- Clinical Trial Site
-
-
Ohio
-
Canton, Ohio, Estados Unidos
- Clinical Trial Site
-
Carlisle, Ohio, Estados Unidos
- Clinical Trial Site
-
Cincinnati, Ohio, Estados Unidos, 45224
- Clinical Trial Site
-
Cincinnati, Ohio, Estados Unidos, 45242
- Clinical Trial Site
-
Columbus, Ohio, Estados Unidos, 43231
- Clinical Trial Site
-
Marion, Ohio, Estados Unidos, 43302
- Clinical Trial Site
-
Marion, Ohio, Estados Unidos
- Clinical Trial Site
-
Mentor, Ohio, Estados Unidos
- Clinical Trial Site
-
Middletown, Ohio, Estados Unidos
- Clinical Trial Site
-
Zanesville, Ohio, Estados Unidos
- Clinical Trial Site
-
-
Oklahoma
-
Norman, Oklahoma, Estados Unidos
- Clinical Trial Site
-
-
Pennsylvania
-
Jenkintown, Pennsylvania, Estados Unidos
- Clinical Trial Site
-
Levittown, Pennsylvania, Estados Unidos
- Clinical Trial Site
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos
- Clinical Trial Site
-
Greer, South Carolina, Estados Unidos
- Clinical Trial Site
-
Myrtle Beach, South Carolina, Estados Unidos
- Clinical Trial Site
-
North Charleston, South Carolina, Estados Unidos
- Clinical Trial Site
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos
- Clinical Trial Site
-
-
Texas
-
Arlington, Texas, Estados Unidos
- Clinical Trial Site
-
Dallas, Texas, Estados Unidos
- Clinical Trial Site
-
Houston, Texas, Estados Unidos, 77030
- Clinical Trial Site
-
Houston, Texas, Estados Unidos, 77074
- Clinical Trial Site
-
Houston, Texas, Estados Unidos
- Clinical Trial Site
-
Laredo, Texas, Estados Unidos
- Clinical Trial Site
-
Longview, Texas, Estados Unidos
- Clinical Trial Site
-
San Antonio, Texas, Estados Unidos, 78205
- Clinical Trial Site
-
San Antonio, Texas, Estados Unidos, 78229
- Clinical Trial Site
-
San Antonio, Texas, Estados Unidos
- Clinical Trial Site
-
San Antonio, Texas, Estados Unidos, 78215
- Clinical Trial Site
-
-
Utah
-
Orem, Utah, Estados Unidos
- Clinical Trial Site
-
-
Virginia
-
Chesapeake, Virginia, Estados Unidos
- Clinical Trial Site
-
Norfolk, Virginia, Estados Unidos
- Clinical Trial Site
-
-
-
-
-
Bekescsaba, Hungria
- Clinical Trial Site
-
Gyula, Hungria
- Clinical Trial Site
-
Komárom, Hungria
- Clinical Trial Site
-
Szekszárd, Hungria
- Clinical Trial Site
-
Vác, Hungria
- Clinical Trial Site
-
-
-
-
-
Daugavpils, Letônia
- Clinical Trial Site
-
Riga, Letônia, LV-1002
- Clinical Trial Site
-
Riga, Letônia, LV-1005
- Clinical Trial Site
-
Riga, Letônia, LV-1006
- Clinical Trial Site
-
Riga, Letônia, LV-1010
- Clinical Trial Site
-
Valmiera, Letônia
- Clinical Trial Site
-
Ventspils, Letônia, LV-3601
- Clinical Trial Site
-
Ventspils, Letônia
- Clinical Trial Site
-
-
-
-
-
Białystok, Polônia
- Clinical Trial Site
-
Sopot, Polônia
- Clinical Trial Site
-
Warszawa, Polônia
- Clinical Trial Site
-
Wrocław, Polônia
- Clinical Trial Site
-
-
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Índia
- Clinical Trial Site
-
Secunderabad, Andhra Pradesh, Índia
- Clinical Trial Site
-
-
Assam
-
Guwahati, Assam, Índia
- Clinical Trial Site
-
-
Karnataka
-
Bangalore, Karnataka, Índia, 560002
- Clinical Trial Site
-
Bangalore, Karnataka, Índia, 560054
- Clinical Trial Site
-
-
Maharashtra
-
Aurangabad, Maharashtra, Índia
- Clinical Trial Site
-
Nagpur, Maharashtra, Índia
- Clinical Trial Site
-
Nashik, Maharashtra, Índia
- Clinical Trial Site
-
Pune, Maharashtra, Índia
- Clinical Trial Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Índia
- Clinical Trial Site
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Índia
- Clinical Trial Site
-
Madurai, Tamil Nadu, Índia
- Clinical Trial Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Índia, 226003
- Clinical Trial Site
-
Lucknow, Uttar Pradesh, Índia
- Clinical Trial Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria include:
- Participants who completed participation in study AMAG-FER-IDA-301 [NCT01114139]
- Female participants of childbearing potential who are sexually active must be on an effective method of birth control and agree to remain on birth control until completion of participation in the study
Key Exclusion Criteria include:
- Experienced a serious adverse event (SAE) related to ferumoxytol in study AMAG-FER-IDA-301
- Female participants who are pregnant, intend to become pregnant, are breastfeeding, or have a positive serum/urine pregnancy test
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Ferumoxytol
Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 [NCT01114139].
Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin <11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) <20% at any evaluation visit, (except study termination visit).
Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV).
The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1.
The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.
|
IV Ferumoxytol
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Change In Hemoglobin From TP Baseline To TP Week 5 Following The First Course Of Ferumoxytol
Prazo: TP Baseline (Day 1), TP Week 5
|
Mean change in hemoglobin from TP Baseline (Day 1) to TP Week 5 following the first dose of ferumoxytol was calculated as: Hemoglobin Change = Hemoglobin (TP Week 5) - Hemoglobin (TP Baseline) TP Baseline was the most recent value measured on/after the screening or the closest monthly evaluation visit prior to Day 1 dosing of Course 1. Change from Baseline used an imputed value of 0 for missing values at the post-baseline visit. |
TP Baseline (Day 1), TP Week 5
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Change In Hemoglobin Following Each Course Of Ferumoxytol From TP Baseline To TP Week 5 Following Each Course Of Ferumoxytol After The First Course
Prazo: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Mean change in hemoglobin from TP Baseline to TP Week 5 following each course of ferumoxytol after the first course was calculated for each participant as: Hemoglobin Change = Hemoglobin (TP Week 5) - Hemoglobin (TP Baseline) The first course of treatment with ferumoxytol for participants who had previously received placebo in AMAG-FER-IDA-301 was considered Course 1. The first course of treatment with ferumoxytol for participants who had previously received ferumoxytol in AMAG-FER-IDA-301 was considered Course 2; subsequent treatment courses were serially numbered. |
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Percentage Of Participants With An Increase In Hemoglobin ≥2.0 g/dL At Any Time From TP Baseline To TP Week 5
Prazo: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Proportion of participants with an increase in hemoglobin ≥2.0 g/dL at any time from TP Baseline to TP Week 5 following each course of ferumoxytol.
The first course of treatment with ferumoxytol for participants who had previously received placebo in AMAG-FER-IDA-301 was considered Course 1.
The first course of treatment with ferumoxytol for participants who had previously received ferumoxytol in AMAG-FER-IDA-301 was considered Course 2; subsequent treatment courses were serially numbered.
|
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Percentage Of Participants Who Achieved A Hemoglobin Level ≥12.0 g/dL At Any Time From TP Baseline To TP Week 5 Following Each Course Of Ferumoxytol
Prazo: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Proportion of participants who achieved a hemoglobin level ≥12.0 g/dL at any time from TP Baseline to TP Week 5 following each course of ferumoxytol.
The first course of treatment with ferumoxytol for participants who had previously received placebo in AMAG-FER-IDA-301 was considered Course 1.
The first course of treatment with ferumoxytol for participants who had previously received ferumoxytol in AMAG-FER-IDA-301 was considered Course 2; subsequent treatment courses were serially numbered.
|
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Mean Change In TSAT Following Each Course Of Ferumoxytol From TP Baseline To TP Week 5 Following Each Course Of Ferumoxytol
Prazo: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Mean change in TSAT from TP Baseline to TP Week 5 following each course of ferumoxytol.
|
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Patient-reported Outcome Measure: Mean Change In Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Questionnaire From TP Baseline To TP Week 5 Following Each Course Of Ferumoxytol
Prazo: TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
The FACIT-Fatigue questionnaire is a 13-item questionnaire designed and validated to specifically assess the presence and impact of treatment on fatigue and related symptoms, such as tiredness, on health-related quality of life in anemic participants with cancer. The questionnaire has 13 items, each measured on a 4-point Likert scale. Scoring ranges from 0 (the most fatigued) to 52 (the least fatigued) points, with higher scores representing better functioning or less fatigue. Mean change in FACIT-Fatigue questionnaire from TP Baseline to TP Week 5 following each course of ferumoxytol was calculated as: FACIT-Fatigue Score Change = FACIT-Fatigue Score (Week 5) - FACIT-Fatigue Score (Baseline). TP Baseline was the most recent value measured on/after the screening or the closest monthly evaluation visit prior to Day 1 dosing in each course. If the TP Week 5 FACIT-Fatigue Score value was missing, the change from TP Baseline was conservatively imputed as zero. |
TP Baseline (Day 1), TP Week 5 for Courses 1, 2, and 3
|
Time To Hemoglobin Increase Of ≥2.0 g/dL Or To A Hemoglobin Level Of ≥12.0 g/dL From Baseline
Prazo: TP Baseline (Day 1) up to TP Week 5 for Courses 1, 2, and 3
|
Days to event was defined as the days from Baseline to the first time the participant met the criteria. Participants without any post-Baseline study visits were not included in this analysis. The first course of treatment with ferumoxytol for participants who had previously received placebo in AMAG-FER-IDA-301 was considered Course 1. The first course of treatment with ferumoxytol for participants who had previously received ferumoxytol in AMAG-FER-IDA-301 was considered Course 2; subsequent treatment courses were serially numbered. |
TP Baseline (Day 1) up to TP Week 5 for Courses 1, 2, and 3
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- AMAG-FER-IDA-303
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Ferumoxytol
-
Dana-Farber Cancer InstituteRetirado
-
National Cancer Institute (NCI)ConcluídoCâncer de próstataEstados Unidos
-
University of EdinburghRoyal Brompton & Harefield NHS Foundation Trust; Royal Infirmary of Edinburgh; Golden Jubilee National HospitalConcluídoMiocardite | Voluntários Saudáveis | Transplante Cardíaco | Sarcóide CardíacoReino Unido
-
Brigham and Women's HospitalConcluídoEmbolia pulmonarEstados Unidos
-
AMAG Pharmaceuticals, Inc.ConcluídoAnemia ferroprivaEstados Unidos, Canadá, Hungria, Índia, Letônia, Polônia
-
National Institute of Neurological Disorders and...National Institutes of Health Clinical Center (CC)Concluído
-
Oregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RescindidoDoenças do Sistema Nervoso | Diagnóstico por imagemEstados Unidos
-
IpsenConcluídoCâncer de Mama Triplo Negativo | Tumores Sólidos | Câncer de Mama ER/PR Positivo | Câncer de mama metastático com metástase cerebral ativaEstados Unidos
-
University of California, Los AngelesConcluído
-
South Florida Family Health and Research CentersConcluído